The FDA Has Lifted The Full Clinical Hold And Cleared PepGen's Investigational New Drug Application To Initiate The FREEDOM-DM1 Phase 1 Study Of PGN-EDODM1 For Myotonic Dystrophy Type 1
Portfolio Pulse from Benzinga Newsdesk
The FDA has lifted the full clinical hold and cleared PepGen's Investigational New Drug application to initiate the FREEDOM-DM1 Phase 1 study of PGN-EDODM1 for Myotonic Dystrophy Type 1.
October 12, 2023 | 11:27 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA's clearance of PepGen's Investigational New Drug application for the FREEDOM-DM1 Phase 1 study could potentially boost the company's stock in the short term.
The FDA's clearance of PepGen's Investigational New Drug application is a significant regulatory milestone for the company. This could potentially lead to increased investor confidence and a boost in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100